Forest Laboratories, Inc. (NYSE:FRX) today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from ...
Tags: Forest Laboratories, definitive agreement, acquisition, Aptalis
Aptalis Pharmaceutical Technologies announced that the European Commission has approved the marketing authorization of new oral granule formulation of Gilead Sciences' Viread, covering 27 countries of the European Union. Viread is ...
Tags: oral granule formulation, Pharmaceutical Technologies, Pharmaceutical
Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma, has announced its co-sponsorship of Controlled Release Society's Young Investigator Award and its participation in the thirty-ninth Annual Meeting & Exposition of the ...
Tags: Aptalis pharmaceutical, professor Berkland, colloids, polymers
The US Court of Appeals for the Federal Circuit has ruled in favor of Aptalis Pharmatech and Cephalon, regarding the validity of two patents covering the Amrix muscle relaxant. The two patents, owned by Aptalis and licensed to ...
Tags: patent, appeal, medical product